SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-20-010201
Filing Date
2020-08-10
Accepted
2020-08-10 16:25:53
Documents
75
Period of Report
2020-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q cara-20200630x10q.htm   iXBRL 10-Q 2434438
2 EX-10.2 cara-20200630xex10d2.htm EX-10.2 99183
3 EX-31.1 cara-20200630xex31d1.htm EX-31.1 12177
4 EX-31.2 cara-20200630xex31d2.htm EX-31.2 11889
5 EX-32.1 cara-20200630xex32d1.htm EX-32.1 10350
  Complete submission text file 0001558370-20-010201.txt   9236411

Data Files

Seq Description Document Type Size
6 EX-101.SCH cara-20200630.xsd EX-101.SCH 53277
7 EX-101.CAL cara-20200630_cal.xml EX-101.CAL 60196
8 EX-101.DEF cara-20200630_def.xml EX-101.DEF 247099
9 EX-101.LAB cara-20200630_lab.xml EX-101.LAB 510725
10 EX-101.PRE cara-20200630_pre.xml EX-101.PRE 421958
11 EXTRACTED XBRL INSTANCE DOCUMENT cara-20200630x10q_htm.xml XML 1733757
Mailing Address 4 STAMFORD PLAZA 107 ELM STREET 9TH FLOOR STAMFORD CT 06902
Business Address 4 STAMFORD PLAZA 107 ELM STREET 9TH FLOOR STAMFORD CT 06902 203-406-3700
Cara Therapeutics, Inc. (Filer) CIK: 0001346830 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36279 | Film No.: 201089731
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences